Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Weiskopf, Kipp ^a,b   Ring, Aaron M ^a,b   Schnorr, Peter J ^a,b   Volkmer, Jens Peter ^a,b   Volkmer, Anne Kathrin ^a,b,c   Weissman, Irving L ^a,b   Garcia, K Christopher ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antibody; Cancer; CD47; Immune checkpoint; Immunotherapy; Macrophage; Molecular engineering; Phagocytosis; SIRP

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD47 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE RECEPTOR; RITUXIMAB; SIGNAL REGULATORY PROTEIN ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GENETIC ENGINEERING; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPHOMA; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; UPREGULATION;

EID: 84890285098     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25773     Document Type: Article

References (6)

1. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286- 99; PMID:19632179; http://dx.doi.org/10.1016/j. cell.2009.05.045
2. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699- 713; PMID:20813259; http://dx.doi.org/10.1016/j. cell.2010.07.044
3. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109:6662-7; PMID:22451913; http://dx.doi. org/10.1073/pnas.1121623109
4. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 2012; 109:6656-61; PMID:22451919; http://dx.doi.org/10.1073/ pnas.1121629109
5. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, et al. Engineered SIRPa variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013; 341:88-91; PMID:23722425; http:// dx.doi.org/10.1126/science.1238856
6. Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell 2008; 31:266-77; PMID:18657508; http://dx.doi.org/10.1016/j.molcel. 2008.05.026